5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01216644 |
Recruitment Status :
Completed
First Posted : October 7, 2010
Last Update Posted : June 19, 2019
|
Sponsor:
Krankenhaus Nordwest
Information provided by (Responsible Party):
Prof. Dr. S.E. Al-Batran, Krankenhaus Nordwest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | March 2017 |
Actual Study Completion Date : | May 2019 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):